作者
Shujun Wang,Xiaowen Hua,Dan Liu,Satyajit Dey Sarker,Lutfun Nahar,Yingying Zhang,Mingquan Guo
摘要
Shaoyao Decoction (SYD) demonstrates therapeutic efficacy in ulcerative colitis (UC), though its active components are still unclear. The present investigation was conducted to comprehensively identify those major constituents of SYD responsible for therapeutic action, focusing on their interaction with important inflammation-related mediators, NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2). In view of this, ultra‑high‑performance liquid chromatography-quadrupole time‑of‑flight tandem mass spectrometry (UHPLC-Q-TOF-MS/MS) coupled with a multi-target affinity ultrafiltration strategy was established for the screening of bioactive compounds. Analysis performed by UHPLC-Q-TOF-MS/MS indicated the presence of 43 compounds within SYD. Positive-ion-mode analysis resulted in the identification of 24 constituents; most of them are flavonoids, including baicalin, jatrorrhizine, and wogonin 7-O-glucuronide. Under negative ion conditions, 23 compounds were detected; these were mainly organic acids and glycosides, including 4,5-dicaffeoylquinic acid, liquiritin, and gallic acid. The bioaffinity ultrafiltration selection profiles indicated that the compounds jatrorrhizine, gallic acid, glycyrrhizic acid, 4,5-dicaffeoylquinic acid, wogonin 7-O-glucuronide, and galloyl paeoniflorin exhibited excellent binding capability with the three inflammatory target enzymes. Notably, jatrorrhizine exhibited binding activity with all three target enzymes in positive ion mode. Gallic acid achieved a binding affinity of 54.68% for IL-6 in negative ion mode, and compounds glycyrrhizic acid, 4,5-dicaffeoylquinic acid, wogonin 7-O-glucuronide, and galloyl paeoniflorin, among others, all exhibited strong binding affinities for both NLRP3 and COX-2. Molecular docking simulations reinforced these binding findings, further substantiating the potential synergistic mechanisms by which SYD components act upon the inflammatory targets. This study characterizes the chemical profiling of SYD and reveals that jatrorrhizine, gallic acid, glycyrrhizic acid, 4,5-dicaffeoylquinic acid, wogonin 7-O-glucuronide, and galloyl paeoniflorin may serve as the primary bioactive components in SYD for treating UC through inhibition of COX-2, NLRP3, and IL-6, thereby offering theoretical support for its clinical use and future development.